Omeq Medical Overview
Omeq Medical is developing a single-use smart needle system for safe, accurate epidural injections. Attached to a standard epidural needle, a special blunted probe repeatedly monitors the dynamic forces exerted by the surrounding tissues and accurately detects needle penetration into the epidural space. Once successful positioning is confirmed with a visual signal, the safety mechanism of the device protects the patient from inadvertent puncture of the spine. Omeq Medical is a portfolio company of Trendlines Medical and received FDA regulatory clearance ("FDA") for its EPiFINDER.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Smart device aims to improve safety of epidurals - ISRAEL21c
Omeq Medical, a company that developed a device to assist physicians in accurately positioning epidural needles, has received regulatory clearance from the US Food and Drug Administration. The device, EpiFinder, will start being marketed in the United States early next year. Omeq Medical is beginning a Series A funding round toward commercialization and is currently in discussions with major US anesthesia product distributors, strategic partners, and investors. The company also plans to conduct a large multicenter study in the United States to show how the EpiFinder device improves performance and successful placement.
InvestmentExpand
growth-positive
Omeq secures FDA approval for epidural injection device
Omeq Medical, part of The Trendlines Group, has received FDA approval for its EpiFinder device, which helps physicians accurately place an epidural needle. The device is sensor-driven, battery-operated, and can be used for safe and accurate epidural injections. It eliminates the need for capital equipment and is compatible with existing epidural syringes. In a clinical trial, the device was found to be safe and effective, allowing physicians to successfully provide epidural blocks. Omeq Medical plans to bring EpiFinder to patients in the US. The device offers an additional objective signal to indicate when the epidural space has been reached, improving targeting and placement accuracy.
Customers
growth-positive
Omeq Medical Penetrates Epidural Market in China Through US$3 Million Funding and Commercialization Agreement With Pharos Medical
Omeq Medical has signed an investment and commercialization agreement with Pharos Medical for its smart epidural device. The agreement includes commercialization of Omeqs device in the Chinese market, with Pharos establishing a production line for the product in China. Omeq expects to complete CFDA clearance and begin production by mid-2020. The agreement is valued at $3 million. Pharos Medical will also become a shareholder of Omeq. The goal of Omeq is to transform epidural procedures with a smart device that improves accuracy and prevents complications.
PartnersInvestment
growth-positive
Israeli startups pitch to China at virtual Tel Aviv roadshow
Omeq Medical, a medical devices start-up, presented its company to Chinese investors at a virtual roadshow organized by TechCode Israel China Innovation Center. The company, which has developed a sensor-based epidural injection system, completed a $1 million funding round and was looking to raise an additional $350,000 from Chinese investors. The Chinese market is of interest to Omeq Medical due to the end of Chinas one-child policy, creating a bigger market for epidurals. The roadshows organized by TechCode Israel aim to expose Chinese investors to a variety of technologies before making investment decisions. Omeq Medicals product aims to provide a more accurate performance of epidural injections, preventing complications and saving hospitals money.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $4.66M |
| Last funding | $850K |
| Stage | Seed |
| Rounds | 4 |
| Investors | 3 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.omeqmedical.com/ |
| Careers | Careers page |
Locations
Bezalel Street 4, Ramat Gan, Israel
Photos & Videos
2 item(s)
